Operator Good day, and welcome to the Vertex Pharmaceuticals fourth quarter 2024 earnings call. All participants will be in a ...

Vertex Pharmaceuticals Inc. will soon lose a member of its leadership team that helped the company achieve major revenue growth over the past decade.

The cystic fibrosis treatment leader exceeded revenue expectations, but missed slightly on earnings per share.

For the full year, Vertex guided for revenue between $11.75 billion and $12 billion, which includes the U.S. launch of cystic fibrosis treatment for patients aged six and older Alyftrek and early ...

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) reported Q4 CY2024 results , with sales up 15.7% year on year to $2.91 ...

波士顿 - Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) 公布的第四季度营收超出分析师预期，周一盘后交易中股价上涨0.8%。这家生物科技公司同时发布了2025财年强劲指引，显示出持续增长的预期。

Vertex (VRTX) stock was trading largely flat post-market after the company released its Q4 earnings report and issued 2025 ...

Vertex Pharmaceuticals forecast annual revenue largely above Wall Street estimates on Monday, banking on robust sales of its ...

Indian billionaire Gautam Adani on Monday said his family will invest over 60 billion rupees ($686.18 million) to launch two ...

In this article we are going to estimate the intrinsic value of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by taking the expected future cash flows and discounting them to their present value.

Meet suzetrigine, a non-opioid that promises to avoid addiction risk. But some experts say it can't replace opioids ...

Vertex Pharmaceuticals Inc. (VRTX) on Monday reported fourth-quarter profit of $913 million. The Boston-based company said it had net income of $3.50 per share.